INTRODUCTION
Pseudomonas aeruginosa is among the three most frequently occurring Gram-negative bacteria in nosocomial infections. [1] [2] [3] Specifically, the bacterium is found in patients suffering from cystic fibrosis. 4 P. aeruginosa possesses various virulence factors such as pigments, rhamnolipids, exotoxin A, proteases, hemolysins and exopolysaccharides. In addition, it contains as other Gram-negative bacteria, LPS in its outer membrane which represents: (i) an essential membrane constituent; (ii) the endotoxin responsible for the severe symptoms of endotoxin shock in generalized infections; and (iii) a surface antigen of high immunogenicity. [5] [6] [7] P. aeruginosa is of interest in many fields of research and thus belongs to the bacteria for which the complete genome sequence has been determined. 8 The chemical structure of various P. aeruginosa LPSs has been determined including studies on the O-chain, 9 the core 10, 11 and lipid A region. 12 One of the prominent structural features in comparison to other LPSs is the occurrence of a carbamoylated residue of L-glycero-D-manno-heptopyranose (cmHep) in the core region which is a chemotaxonomic marker for the whole genus. 13 We were interested to learn whether: (i) this substituent influences the antigenicity of the inner core region; (ii) specific antibodies can be generated against epitopes containing cmHep; and (iii) such antibodies can be used to identify P. aeruginosa strains in a clinical diagnostic setting.
Here we describe the synthesis (Fig. 1 ) of oligosaccharides containing cmHep which represent partial structures ( Fig. 2 ) of the inner core region of LPS from P. aeruginosa strain H4, 14 their ability to induce an antibody response in mice and their reactivity with antibodies against LPS.
The disaccharide allyl 2-acetamido-2-deoxy-α-D-galactopyranosyl-(1→3)-7-O-carbamoyl-L-glyceroα-D-manno-heptopyranoside 5 (GalNAc-cmHep-allyl) was synthesized starting from 1 and 2. Compound 5, cmHep-allyl and the disaccharide cmHep-(1→3)-Hep-allyl were converted into cysteamine-spacered derivatives and conjugated to bovine serum albumin (BSA) to yield the neoglycoconjugates 7-9, respectively. These conjugates were used to immunize mice and to prepare monoclonal antibodies (mAbs) which were characterized in comparison to mAbs obtained after immunization with heat-killed Pseudomonas aeruginosa strain H4. Two antibodies obtained after immunization with the neoglycoconjugates bound strongly to cmHep-BSA and with lower affinity to cmHep-Hep-BSA but did not bind to GalNAc-cmHep-BSA or to H4 LPS. Another antibody obtained after immunization with heat-killed bacteria bound to LPS and GalNAc-cmHep-BSA but not to cmHep-Hep-BSA or cmHep-BSA
MATERIALS AND METHODS

Bacteria and bacterial LPS
The cultivation of P. aeruginosa strain H4 and the extraction of LPS was as described elsewhere. 11 Heat-killed bacteria were prepared by boiling overnight cultures for 1 h at 100°C. Cells were washed twice in water, lyophilized and suspended in PBS at a concentration of 1 mg/ml.
Synthetic neoglycoconjugate antigens
A suspension of 1 (31 mg, 65 µmol), molecular sieves 4Å (200 mg) and 2 (20 mg, 55 µmol) in dry dichloromethane (1.5 ml) was cooled to -15°C and stirred under argon for 1 h. A solution of 0.4 M TMSO triflate in CH 2 Cl 2 (0.72 ml) was added and stirring was continued for 90 min. Solid K 2 CO 3 (200 mg) was added, the suspension was stirred for 1 h and filtered over Celite. The filtrate was concentrated and purified by column chromatography on silica gel (1:1 A solution of triphenylphosphine (20 mg, 76 µmol) in dry CH 2 Cl 2 (0.1 ml) was added to a solution of 3 (29 mg, 43 µmol) and acetyl chloride (10 µl, 14.0 µmol) in CH 2 Cl 2 (1 ml). The solution was stirred for 12 h at room temperature, then dry pyridine (1 ml) and acetic anhydride (0.1 ml) were added and stirring was continued for 3 h. MeOH (0.5 ml) was added and the solution was coevaporated twice with toluene. The solution was concentrated and the residue was chromatographed on silica gel 
To a stirred solution of 4 (18.4 mg, 27 µmol) and NH 4 HCO 3 (200 mg) in THF (3 ml), 25% aqueous NH 3 (0.8 ml) was added dropwise. Then MeOH (0.1 ml) was added, and a homogeneous phase was obtained. The solution was stirred for 24 h at room temperature, then concentrated and co-evaporated three times with addition of EtOH. The residue was chromatographed on silica gel (15 
BSA-conjugate 7
A solution of 6 (3 mg, 5 µmol) in 0.1 M aqueous NaHCO 3 (1 ml) was vigorously stirred with a solution of thiophosgene (1 µl, 13 µmol) in chloroform (1 ml) for 2 h at room temperature. The organic layer was removed and the aqueous phase was washed twice with CHCl 3 (2 ml) and purged with N 2 . A solution of bovine serum albumin (3 mg) in 0.1 M aqueous NaHCO 3 /0.3 M aqueous NaCl was added and stirring was continued for 48 h. The solution was passed through a column of Sephadex G-25 using 10 mM NaHCO 3 as eluent. Ninhydrin-positive fractions were collected, dialyzed against water and lyophilized to give 7 as a colorless powder. Yield: 2.9 mg.
The neoglycoproteins 8 and 9, containing the ligand cmHep and cmHep-(1→3)-Hep, respectively, were synthesized as Neoglycoproteins containing epitopes of the inner core region of P. aeruginosa RNA group I LPS 127 described. 1 The amount of ligand present in the conjugates was determined by MALDI-time of flight-mass spectrometry indicating an average molecular mass of 71196 for 7, 70922 for 8, and 71143 for 9. Based on the mass of the BSA-standard (m: 66455), the ratios (mol ligand/mol BSA) 7.7:1, 11:1, and 7.7:1 were calculated for 7, 8, and 9, respectively.
Monoclonal antibodies
BALB/c mice were immunized with synthetic neoglycoconjugates by a protocol described by Stähli et al. 15 Mice (groups of 4) were injected on day 0 with a cocktail of the neoglycoconjugates 7-9 (20 µg each) in PBS (125 µl) emulsified with an equal volume of Freund's complete adjuvant. One aliquot (50 µl) was injected i.p. and four aliquots (50 µl each) were injected s.c. at four different sites. On day 28, again 20 µg of each antigen in PBS (50 µl) emulsified with an equal volume of Freund's incomplete adjuvant were injected i.p. Seven days later, the mice were bled from the tail vein and the sera were tested for the presence of antibodies against the immunizing antigens. The mouse with the highest titer received three booster injections of a cocktail containing compound 7 (50 µg), 8 (100 µg) and 9 (50 µg) in PBS on days 75, 76 and 77; the first one i.v., the least two i.p. Two days after the last injection, the animal was exsanguinated and the spleen was removed. Spleen cells were prepared and fused with myeloma cells in a ratio of 2:1. Hybridomas were screened by ELISA using the immunizing antigens or LPS as described in the respective references. Relevant hybridomas were cloned at least thrice by limiting dilution, isotyped with a commercially available isotyper kit (Bio-Rad), and purified by affinity chromatography using protein G. MAb against heat-killed bacteria were prepared as follows. BALB/c mice (groups of 4) were injected intravenously on day 0, 7, 14 and 21 with 20, 20, 60 and 120 µg of bacteria, respectively, in 0.5 ml of PBS. The animals received three booster injections of 200 µg each on day 116, 117 and 118. The first injection was given i.v., the last two injections i.p., followed by fusion on day 120. Screening was performed by ELISA using LPS as antigen. The positive hybridomas were tested also with the neoglycoconjugates. One antibody was obtained which belonged to the IgM class. It was purified as follows. 16 Hybridoma cells were grown in the MiniPerm system (Heraeus, Germany). A column (50 x 1 cm) of sephacryl 200 was equilibrated for 3 h with phosphate buffer (5 mM; pH 8.0) at a flow rate of 30 ml/h, loaded with hybridoma supernatant (1 ml) and eluted with the same buffer supplemented with 1.7 M NaCl at a flow rate of 11 ml/h. Fractions were collected, tested by ELISA for antibody activity and appropriately combined. Purity was con-firmed by SDS-PAGE and the protein content was determined by the bicinchoninic acid assay (Pierce). 17 
ELISA using neoglycoconjugate antigens
Neoglycoconjugates were coated onto MaxiSorp microtiter plates (U-bottom, Nunc). Antigen solutions were adjusted to equimolar concentrations based on the amount of ligand present in the respective glycoconjugate. If not stated otherwise, 50 µl volumes were used. Microtiter plates were coated with the respective antigen solution in carbonate buffer (50 mM, pH 9.2) at 4°C overnight using a concentration range from 1 pmol to 1 nmol of ligand per ml of coating solution which corresponded to 500 pg to 500 ng of protein per well. Plates were washed twice with distilled water and twice in PBS supplemented with Tween 20 (0.05%, Bio-Rad) and thimerosal (0.01%, PBS-T). Plates were then blocked with PBS-T supplemented with casein (2.5%, PBS-TC) for 1 h at 37°C on a rocker platform followed by two washings. Appropriate antibody dilutions in PBS-TC supplemented with 5% BSA (PBS-TCB) were added and incubated for 1 h at 37°C. After two washings, peroxidase conjugated goat anti-mouse IgG (heavy and light chain specific; Dianova), or IgM (µ-chain specific; Dianova) was added (both diluted 1:1000) and incubation was continued for 1 h at 37°C. After three washings in PBS-T, the plates were washed once in substrate buffer (0.1 M sodium citrate, pH 4.5). Substrate solution was freshly prepared and was composed of azino-di-3ethylbenzthiazolinsulfonic acid (1 mg) dissolved in substrate buffer (1 ml) with sonication in an ultrasound water bath for 3 min followed by the addition of hydrogen peroxide (25 µl of a 0.1 % solution). After 30 min at 37°C, the reaction was stopped by the addition of aqueous oxalic acid (2%) and the plates were read by a microplate reader (Dynatech MR 5000) at 405 nm. Tests were run in quadruplicates with confidence values not exceeding 10%.
ELISA using LPS antigens
When LPS was used as an antigen in ELISA, microtiter polyvinyl plates (Falcon 3911; Becton Dickinson) were coated with LPS of varying concentration (0.04-5 µg/ml, corresponding to 10-1250 pmol/ml based on a calculated average molecular weight of 4 kDa) diluted in PBS (pH 7.2) and were incubated overnight at 4°C. PBS and PBS-containing solutions were supplemented with thimerosal (0.01%). Further incubation steps were performed at 37°C under gentle agitation. The coated plates were washed 4 times with PBS and were blocked for 1 h with PBS supplemented with casein (2.5%, Sigma; PBS-C; 200 µl per well). Serial dilutions of mAb diluted in PBS-C were subsequently added, and the mixture was incubated for 1 h at 37°C. After washing as described above, secondary antibodies diluted in PBS-C (same source and dilution as above) were added. After four washings in PBS and two washings in substrate buffer, the remaining steps were done as described for ELISA using neoglycoconjugate antigens.
RESULTS AND DISCUSSION
Chemical synthesis of neoglycoconjugates
For the synthesis of the disaccharide α-D-GalpNAc-(1→3)-7-O-carbamoyl-L-gro-D-manHepp-(1→Oallyl) (5), the known 18 trichloroacetimidate donor 1 was coupled with the previously reported 19 heptoside acceptor 2 in the presence of TMSO-triflate in dichloromethane to afford the disaccharide 3 in 73% yield as a ~10:1 α/β mixture, which was separated by silica gel chromatography. Reduction of the 2-azido-2-deoxy-group of the disaccharide 3 using a variant of the Staudinger reaction 20 furnished the 2-acetamido-2-deoxy derivative 4 in 81% yield. Due to the formation of a free amino group in the 2-position, the reaction mixture was re-acetylated with pyridine/acetic anhydride prior to work-up of the reaction. Similar to previous results, the 6,7-O-carbonate group of the heptopyranoside unit could be converted in good regioselectivity into the 7-O-carbamoyl derivative with concomitant removal of five O-acetyl groups using ammonia/ammonium hydrogencarbonate buffer. Chromatography on silica gel allowed the removal of a small amount of the 6-O-substituted isomer (19%) and furnished the target compound 5 in 76% yield. The 1 H-and 13 C-NMR data of the disaccharide were in full agreement with the structural assignments and compare favorably with the data of the corresponding unit in a tetrasaccharide obtained from LPS of P. aeruginosa mutant H4. 11 In particular, the presence and position of the carbamoyl group was assigned on the basis of the 13 C-NMR chemical shift observed at 160.19 ppm (NH-C=O) and 66.51 ppm for C-7 of the heptose unit.
The allyl group was then converted into a spacer-group by radical addition of cysteamine hydrochloride. 21, 22 Activation of the terminal amino group with thiophosgene and coupling of the resulting isothiocyanate to BSA gave the corresponding neoglycoprotein after purification on Sephadex G-25 and desalting. 23 
Preparation and characterization of monoclonal antibodies (mAbs)
The glycoconjugates were used to immunize mice from which spleen cells were used to prepare mAbs. Two anti-bodies S63-6-8 and S63-6-13 were obtained which both belonged to the IgG 1 isotype and were similar in epitope specificity. Another set of mAbs was obtained after immunization with heat-killed P. aeruginosa H4 from which we selected those binding to LPS and to at least one of the three neoglycoconjugates. One antibody S60-4-7 (IgM) fulfilled these requirements. The two mAbs S63-6-8 and S63-6-13 did not bind to LPS or GalNAc-cmHep-BSA but bound strongly to cmHep-BSA and, to a much lesser extent, to cmHep-Hep-BSA. Binding to cmHep-BSA was still seen at antibody concentrations as low as 1 ng/ml and at antigen coating concentrations of 6 pmol/ml (Fig. 3C) . Although the binding of mAb S63-6-8 to cmHep-Hep-BSA was significantly weaker (Fig. 3B ) and only seen at Neoglycoproteins containing epitopes of the inner core region of P. aeruginosa RNA group I LPS 129 antigen coating concentrations higher than 100 pmol/ml it was clearly distinguishable from the negative results obtained with GalNAc-cmHep-BSA (Fig. 3A) . The results obtained with mAb S63-6-13 were comparable and are, therefore, not shown. Among the antibodies obtained after immunization with heat-killed bacteria we found one, S60-4-7 (IgM), which bound to H4 LPS and to GalNAc-cmHep-BSA but not to cmHep-Hep-BSA or cmHep-BSA. Checkerboard titrations of mAb S60-4-7 with LPS or GalNAc-cmHep-BSA are shown in Figure 4A and 4B, respectively. The results show that binding to the natural LPS was stronger than that to the synthetic neoglycoconjugate. Binding to the latter was particularly week when low amounts of antigen were used to coat the ELISA plates. Binding to wild-type, i.e. smooth LPS, was not observed (data not shown); however, a detailed characterization of the reactivity with other rough mutant or smooth LPS have not so far been done.
Nevertheless, we have learnt from this study that cmHep is immunogenic. This is true for cmHep in natural LPS embedded in the outer membrane since heat-killed bacteria were successfully used to immunize mice as well as for the synthetic neoglycoconjugates described herein. The immunogenicity of cmHep was surprising to us since we have reported earlier that LPS with terminal L-glycero-Dmanno-heptose residues are extremely poor immunogens. Whereas antibodies against all types of LPS were easily obtained by us and others, immunization with Salmonella enterica serovar Minnesota rough mutants of the Rdchemotype, the LPS of which is terminated by heptose, gave only in a few experiments a positive antibody response. 24 Using neoglycoconjugates containing heptose mono-or disaccharide as a ligand, we were unable to generate mAbs. This failure was interpreted as a result of the structural similarity of the D-manno-configured heptose to D-mannose which occurs on many mammalian glycoproteins and may thus not be recognized as foreign.
Since cmHep is immunogenic and since it occurs according to our present knowledge exclusively in Pseudomonas, we are further trying to generate mAbs against cmHep-containing epitopes which are also exposed in smooth LPS of clinically relevant strains of P. aeruginosa. Such antibodies would be useful for the rapid identification of Pseudomonas in clinical material and may be also of therapeutic use against infections caused by this Gram-negative bacterium. 
